Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;17(5):283-92.
doi: 10.1016/j.molmed.2011.01.012. Epub 2011 Mar 1.

Targeting mutant fibroblast growth factor receptors in cancer

Heidi Greulich  1 , Pamela M Pollock
Affiliations
Review

Targeting mutant fibroblast growth factor receptors in cancer

Heidi Greulich et al. Trends Mol Med. 2011 May.

Abstract

Fibroblast growth factor receptors (FGFRs) play diverse roles in the control of cell proliferation, cell differentiation, angiogenesis and development. Activating the mutations of FGFRs in the germline has long been known to cause a variety of skeletal developmental disorders, but it is only recently that a similar spectrum of somatic FGFR mutations has been associated with human cancers. Many of these somatic mutations are gain-of-function and oncogenic and create dependencies in tumor cell lines harboring such mutations. A combination of knockdown studies and pharmaceutical inhibition in preclinical models has further substantiated genomically altered FGFR as a therapeutic target in cancer, and the oncology community is responding with clinical trials evaluating multikinase inhibitors with anti-FGFR activity and a new generation of specific pan-FGFR inhibitors.

PubMed Disclaimer

Figures

Figure 2
Figure 2
Alignment of altered amino acids encoded by somatic mutations found in FGFRs that are known or likely to be oncogenic (Table 1). Unique amino acid substitutions are represented by green circles. Amino acid numbers are derived from the following reference transcripts: FGFR1, NM_000604; FGFR2, NM_022970; FGFR3, NM_000142; FGFR4, NM_002011. Yellow, Ig-like domains; red, kinase domains.
Figure 1
Figure 1
Schematic diagram of signal transduction pathway activated by ligand-stimulated FGFRs. Ligand specificity is determined in part by an alternative splicing event in the C-terminal half of the third immunoglobulin domain (bright blue) in which either exon 8 or exon 9 can be used, producing the IIIb and IIIc isoforms, respectively. Ligand binding results in receptor autophosphorylation in the kinase domain region and phosphorylation of FRS2, which initiates a signaling cascade resulting in activation of the AKT and ERK downstream signaling pathways.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome biology. 2001;2 REVIEWS3005. - PMC - PubMed
    1. Zhang X, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281:15694–15700. - PMC - PubMed
    1. Yan G, et al. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol. 1993;13:4513–4522. - PMC - PubMed
    1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–129. - PubMed
    1. Chesi M, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260–264. - PMC - PubMed

MeSH terms

Substances